Nuvalent (NASDAQ:NUVL) Hits New 52-Week High – Time to Buy?

Shares of Nuvalent, Inc. (NASDAQ:NUVL) hit a new 52-week high during trading on Wednesday . The company traded as high as $123.62 and last traded at $123.5150, with a volume of 339209 shares. The stock had previously closed at $123.44.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on NUVL shares. Wedbush downgraded shares of Nuvalent from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $125.00 to $124.00 in a research report on Tuesday, June 9th. Leerink Partners set a $165.00 target price on shares of Nuvalent in a research note on Wednesday, June 3rd. Lifesci Capital cut Nuvalent from an “outperform” rating to a “hold” rating and set a $124.00 price target on the stock. in a report on Tuesday, June 9th. Cantor Fitzgerald downgraded Nuvalent from an “overweight” rating to a “neutral” rating in a research note on Tuesday, June 9th. Finally, UBS Group lowered Nuvalent from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $138.00 to $124.00 in a report on Wednesday, June 10th. Four equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $127.73.

Nuvalent Stock Down 0.0%

The business’s fifty day moving average is $107.67 and its 200-day moving average is $104.38. The company has a market cap of $9.76 billion, a PE ratio of -20.38 and a beta of 1.15.

Nuvalent (NASDAQ:NUVL) last announced its earnings results on Thursday, May 7th. The company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.04). During the same quarter last year, the firm earned ($1.18) EPS. Analysts forecast that Nuvalent, Inc. will post -5.74 EPS for the current fiscal year.

Insider Buying and Selling at Nuvalent

In other news, CEO James Richard Porter sold 30,000 shares of the company’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $88.53, for a total value of $2,655,900.00. Following the completion of the sale, the chief executive officer directly owned 324,879 shares in the company, valued at $28,761,537.87. This represents a 8.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Deborah Ann Miller sold 5,500 shares of the firm’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $107.84, for a total value of $593,120.00. Following the completion of the transaction, the insider directly owned 59,634 shares in the company, valued at approximately $6,430,930.56. This represents a 8.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 126,953 shares of company stock worth $12,612,264. 5.02% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Hudson Bay Capital Management LP bought a new stake in Nuvalent during the 3rd quarter worth approximately $1,297,000. HighVista Strategies LLC boosted its position in shares of Nuvalent by 84.9% in the third quarter. HighVista Strategies LLC now owns 93,294 shares of the company’s stock worth $8,068,000 after purchasing an additional 42,834 shares during the period. Aberdeen Group plc increased its stake in shares of Nuvalent by 115.4% in the fourth quarter. Aberdeen Group plc now owns 165,177 shares of the company’s stock worth $16,615,000 after purchasing an additional 88,489 shares in the last quarter. Cantor Fitzgerald L. P. bought a new stake in shares of Nuvalent during the 3rd quarter valued at $1,946,000. Finally, Nicholas Investment Partners LP raised its position in shares of Nuvalent by 29.2% during the 4th quarter. Nicholas Investment Partners LP now owns 160,483 shares of the company’s stock valued at $16,143,000 after purchasing an additional 36,305 shares during the period. 97.26% of the stock is owned by hedge funds and other institutional investors.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.